Expression of PTEN and mTOR in pancreatic neuroendocrine tumors

Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms

(2012) S. Crippa et al.   ANNALS OF ONCOLOGY

Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors

(2012) Jonathan R. Strosberg et al.   ANNALS OF SURGERY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Hepatocellular tumors: Immunohistochemical analyses for classification and prognostication

(2011) Regina Cheuk-Lam Lo et al.   Chinese Journal of Cancer Research

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Endocrine Tumors

(2010) Kjell Öberg   SEMINARS IN ONCOLOGY

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

(2009) Takashi Shida et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors

(2008) David C. Metz et al.   GASTROENTEROLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY